Quick Answer
Transcode Therapeutics, Inc. reported Common Stock Shares Outstanding of 1.03 million shares for the year ending 2024.
- Transcode Therapeutics, Inc. showed an increase of +5,312.3% in Common Stock Shares Outstanding from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 4.64 million shares | Q3 2021: 12.90 million shares | Q1 2022: 12.98 million shares | Q2 2022: 12.98 million shares | Q3 2022: 12.98 million shares | Q1 2023: 15.82 million shares | Q2 2023: 1.95 million shares | Q3 2023: 10.69 million shares | Q1 2024: 5.81 million shares | Q2 2024: 7.27 million shares | Q3 2024: 17.27 million shares | Q4 2024: 36,753 shares | Q1 2025: 23.34 million shares | Q2 2025: 833,683 shares | Q3 2025: 833,683 shares.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Common Stock Shares Outstanding has declined by 77.8%.
- Historical annual values: Fiscal year 2024: 1.03 million shares | Fiscal year 2023: 19,014 shares | Fiscal year 2022: 16,222 shares | Fiscal year 2021: 12.90 million shares | Fiscal year 2020: 4.64 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: